Edwards Lifesciences Reports PASCAL Trial Results for Tricuspid Regurgitation
Edwards Lifesciences said PASCAL was superior to medical therapy on the CLASP II TR trial’s six-month primary endpoint. At one year, 80% of treated patients versus 30% of controls had no more than moderate tricuspid regurgitation; quality-of-life scores improved 18 points.
Edwards Lifesciences Corporation said PASCAL was superior to medical therapy for the CLASP II TR trial’s six-month primary endpoint. At one year, 80% of treated patients versus 30% of controls had ≤ moderate tricuspid regurgitation; quality-of-life scores improved 18 points.Material DetailsContext…